Owen Haskins, Managing Editor, Coloproctology News

Latest posts

Ulcerative Colitis: vedolizumab out performs adalimumab for clinical remission and endoscopic improvement

The IKBFU center for clinical research scientists have participated in the international VARSITY clinical research study, the world's first study aimed at finding the most effective drug among anti-inflammatory drugs for the treatment of ulcerative colitis. The results, ‘Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis’, were published in The New England Journal of Medicine.

6th Portsmouth CME Symposium

Start Date
26 May 2020
End Date
28 May 2020
Queen Alexandria Hospital and the University of Portsmouth
Lakeside 2000 Auditorium

Study finds Cook Medical’s Hemospray is 98% successful in treating GI bleeding

A new, multi-centre study on Cook Medical’s Hemospray Endoscopic Hemostat device has revealed that the use of Hemospray demonstrated a more than 98% successful hemostasis rate, while the 30-day rebleeding rate was 10%. The results, ‘Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy’, were published in the April 2019 edition of Gastrointestinal Endoscopy.

New approach to bowel cancer analysis could lead to better prognosis for patients

Researchers from Queen’s University have demonstrated how a precise integration of the results of both pathological and molecular analysis of tumour and normal tissue from the bowel can ensure a correct interpretation of the data, providing a more accurate result that can underpin better treatment options for bowel cancer patients. The paper, ‘Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition,’ in the journal The Journal of Pathology.

Ten-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study, ‘Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings’, published in JAMA Internal Medicine.